Humana Inc. (NYSE:HUM – Get Free Report) traded down 2.9% on Friday after JPMorgan Chase & Co. lowered their price target on the stock from $593.00 to $575.00. JPMorgan Chase & Co. currently has a neutral rating on the stock. Humana traded as low as $496.04 and last traded at $497.79. 792,382 shares changed hands during mid-day trading, a decline of 31% from the average session volume of 1,144,073 shares. The stock had previously closed at $512.91.
Other equities research analysts have also recently issued research reports about the stock. Deutsche Bank Aktiengesellschaft increased their price target on shares of Humana from $468.00 to $628.00 and gave the company a “buy” rating in a research report on Monday, August 7th. StockNews.com upgraded Humana from a “buy” rating to a “strong-buy” rating in a report on Friday, November 3rd. Morgan Stanley lowered their price target on Humana from $637.00 to $624.00 and set an “overweight” rating for the company in a research report on Wednesday, August 30th. TD Cowen reduced their target price on Humana from $616.00 to $613.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 15th. Finally, Royal Bank of Canada raised their price target on Humana from $594.00 to $599.00 and gave the stock an “outperform” rating in a research note on Thursday, November 2nd. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $590.28.
Institutional Inflows and Outflows
Humana Trading Down 3.0 %
The company has a current ratio of 1.37, a quick ratio of 1.37 and a debt-to-equity ratio of 0.56. The stock has a market capitalization of $61.23 billion, a PE ratio of 20.72, a P/E/G ratio of 1.33 and a beta of 0.61. The stock has a 50 day moving average price of $496.41 and a 200-day moving average price of $486.16.
Humana (NYSE:HUM – Get Free Report) last released its quarterly earnings results on Wednesday, November 1st. The insurance provider reported $7.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.15 by $0.63. Humana had a return on equity of 21.03% and a net margin of 2.95%. The business had revenue of $26.42 billion during the quarter, compared to the consensus estimate of $25.57 billion. During the same period in the previous year, the company posted $6.88 EPS. The business’s quarterly revenue was up 15.9% compared to the same quarter last year. Sell-side analysts expect that Humana Inc. will post 28.28 earnings per share for the current year.
Humana Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, January 26th. Stockholders of record on Friday, December 29th will be paid a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 0.71%. The ex-dividend date is Thursday, December 28th. Humana’s dividend payout ratio is presently 14.68%.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
- Five stocks we like better than Humana
- What Are the FAANG Stocks and Are They Good Investments?
- 3 large caps with red hot RSIs with upside
- Earnings Per Share Calculator: How to Calculate EPS
- Johnson Controls International: Nothing but upside for investors
- How to Buy Bitcoin Stock: 3 Easy Ways to Do It
- Unity Software’s resilient rebound post-earnings setback
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.